secwatch.observer — SEC 8-K summary
======================================

Issuer:     FOXO TECHNOLOGIES INC. (FOXO)
CIK:        0001812360
Form:       8-K
Filed at:   2026-07-06T20:05:39+00:00
Accession:  0001493152-26-032156
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FOXO Technologies mid-year update: Q1 revenue $5.1M, loss narrowed, potential $10M+ Vector acquisition
--------------------------------------------------------------------------------

- Q1 2026 net revenues $5.1M vs $3.2M YoY; operating loss narrowed to $0.3M from $1.5M.
- Effected 1:3,000 reverse stock split; exchanged ~$7.8M Series A Preferred into non-convertible debt to reduce dilution.
- Entered agreement with former CEO Jon Sabes to license epigenetics IP for 3% royalty (cap $1.3M) and ten-year option for majority ownership.
- Myrtle Recovery Centers operating at 92% occupancy; seeking expansion to 32 beds; annualized admissions ~700 in 2026.
- Vector BioSource evaluating acquisition that could add >$10M annual revenue; company considering uplisting to NYSE American.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812360/000149315226032156/0001493152-26-032156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812360/000149315226032156/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-032156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer